Spotlight On... Adherium wins approval to sell its 'smart' inhaler devices in Canada; Alnylam takes another RNAi candidate to trials; PsiOxus Therapeutics begins trials for intraperitoneal cancer candidate; and more...

Australia's Adherium Group announced clearance to sell its SmartTurbo and SmartTouch "smart inhaler" devices in Canada. They improve adherence by tracking usage and sending reminders. The SmartTurbo is used with AstraZeneca's ($AZN) Symbicort Turbuhaler and the SmartTouch works with a variety of metered dose inhalers, including those made by GlaxoSmithKline ($GSK). Adherium Group CEO Garth Sutherland said, "We are committed to ensuring our devices, which are proven to significantly improve the quality of life for people with respiratory diseases, are able to be supplied into all the major markets of the world. This clearance to market allows us to add Canada to the international markets which we already supply, including the US, Europe, China, Australia and New Zealand." Release

> RNAi specialist Alnylam has initiated a Phase I/II clinical trial of a subcutaneously administered investigational candidate for the treatment of Primary Hyperoxaluria Type 1. More

> Oxford, England's PsiOxus Therapeutics announced that the first patient has been treated in a trial of intravenous paclitaxel with the intraperitoneal oncolytic virotherapy enadenotucirev. More

Suggested Articles

Takeda forged a feasibility pact to see whether it could pair a plasma-based therapy with Elektrofi's microparticle delivery tech.

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.